Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#4669 Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial

Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.

Conference:

Presenting Author:

Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,

Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,

#4319 Everolimus combined with orlistat inhibits the development of neuroendocrine tumours by inhibiting the mTOR-PI3K-Akt signalling pathway

Introduction: Everolimus, an mTOR inhibitor, has demonstrated efficacy in NET treatment. Orlistat, used primarily for obesity management, inhibits fat absorption. This study investigates the potential synergistic effects of Everolimus combined with Orlistat on the development of NETs.

Conference:

Presenting Author:

Authors: Xu L, Tang Q, Ye M,

Keywords: Everolimus, orlistat, mTOR, PI3K/Akt, signalling pathway,

#4316 Combination of sorafenib and everolimus regresses pancreatic neuroendocrine tumour significantly in vitro and vivo

Introduction: PNET is a rare group of highly heterogeneous tumours with neuroendocrine differentiation properties. Everolimus is the most promising drug for progressive well-differentiated pNETs. Sorafenib's anti-tumour activity may involve regulation of the mTOR pathway.

Conference:

Presenting Author: Zheng H

Authors: Zheng H,

Keywords: sorafenib, everolimus, pancreatic neuroendocrine tumour, mTOR,

#4306 EVENET: Randomised phase II trial of everolimus 5mg vs. 10mg daily in patients with neuroendocrine tumours

Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.

Conference:

Presenting Author:

Authors: Riechelmann R, Campos A, Durant L, Bulzico D,

Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,